Deutsche Bank AG Has $160.19 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Deutsche Bank AG grew its holdings in shares of Humana Inc. (NYSE:HUM) by 18.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 631,371 shares of the insurance provider’s stock after acquiring an additional 97,071 shares during the period. Deutsche Bank AG’s holdings in Humana were worth $160,185,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Deerfield Management Company L.P. Series C acquired a new position in Humana during the 4th quarter worth about $233,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in Humana by 38.0% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 110,786 shares of the insurance provider’s stock valued at $28,108,000 after acquiring an additional 30,522 shares during the last quarter. Cary Street Partners Financial LLC acquired a new stake in Humana during the 4th quarter valued at approximately $694,000. Aptus Capital Advisors LLC raised its holdings in Humana by 12.0% during the 4th quarter. Aptus Capital Advisors LLC now owns 859 shares of the insurance provider’s stock worth $218,000 after purchasing an additional 92 shares during the last quarter. Finally, Accredited Wealth Management LLC acquired a new position in shares of Humana in the 4th quarter worth approximately $101,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

Shares of NYSE:HUM opened at $249.67 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market cap of $30.13 billion, a PE ratio of 25.09, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The stock’s fifty day simple moving average is $265.21 and its two-hundred day simple moving average is $270.30. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. During the same period last year, the firm earned $7.23 earnings per share. The firm’s revenue was up 8.4% on a year-over-year basis. As a group, analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.42%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio is presently 25.04%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HUM shares. Truist Financial increased their price objective on shares of Humana from $290.00 to $325.00 and gave the stock a “hold” rating in a research report on Friday, April 11th. Robert W. Baird boosted their price objective on Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Piper Sandler raised their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Barclays boosted their price target on Humana from $270.00 to $322.00 and gave the company an “equal weight” rating in a research note on Friday, April 11th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $287.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.